The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients
© 2023. The Author(s)..
BACKGROUND: There is pressing needs to find the biomarker in the selection of neoadjuvant therapy in postmenopausal luminal breast cancer patients. We examined the hypothesis that PIK3CA mutations and low phosphatase and tensin homolog (PTEN) expression affect the response to neoadjuvant therapy and prognosis in postmenopausal luminal breast cancer patients.
METHODS: Postmenopausal patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, up to stage II, who underwent neoadjuvant chemotherapy (NAC; n = 60) or neoadjuvant endocrine therapy (NAE; n = 55) were selected. PIK3CA exon 9 and exon 20 mutations were screened by high resolution melting analysis and confirmed by Sanger sequence. PTEN expression was evaluated by immunohistochemistry. The relationships among PIK3CA mutations, PTEN expression, clinicopathological features, the pathological effect of neoadjuvant therapy, recurrence-free survival (RFS) and overall survival were analyzed.
RESULTS: Among 115 patients, PIK3CA mutations and low PTEN expression before treatment were detected in 35 patients (30.4%) and in 28 patients (24.3%), respectively. In the NAC group, tumor with PIK3CA mutations showed significantly poorer response than tumor with PIK3CA wild-type (p = 0.03). On the other hand, in the NAE group, there was no significant difference in pathological therapeutic effect between tumor with PIK3CA mutations and tumor with PIK3CA wild-type (p = 0.54). In the NAC group, the log-rank test showed no difference in RFS between patients with PIK3CA mutations and PIK3CA wild-type (p = 0.43), but patients with low PTEN expression showed significantly worse RFS compared to patients with high PTEN expression (5 year RFS 0.64 vs. 0.87, p = 0.01). In the Cox proportional hazards model for RFS, PTEN expression, progesterone receptor, and pathological therapeutic effect were predictive factors for time to recurrence (All p < 0.05).
CONCLUSIONS: PIK3CA mutations are associated with resistance to NAC but do not affect the response to NAE. Low PTEN expression does not affect response to either NAC or NAE but correlates with shorter RFS in patients who received NAC. These biomarkers will be further evaluated for clinical use to treat postmenopausal luminal breast cancer patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
BMC cancer - 23(2023), 1 vom: 27. Apr., Seite 384 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hayama, Shouko [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.05.2023 Date Revised 25.08.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12885-023-10853-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356098974 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356098974 | ||
| 003 | DE-627 | ||
| 005 | 20231226065734.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-023-10853-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM356098974 | ||
| 035 | |a (NLM)37106324 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hayama, Shouko |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.05.2023 | ||
| 500 | |a Date Revised 25.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: There is pressing needs to find the biomarker in the selection of neoadjuvant therapy in postmenopausal luminal breast cancer patients. We examined the hypothesis that PIK3CA mutations and low phosphatase and tensin homolog (PTEN) expression affect the response to neoadjuvant therapy and prognosis in postmenopausal luminal breast cancer patients | ||
| 520 | |a METHODS: Postmenopausal patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, up to stage II, who underwent neoadjuvant chemotherapy (NAC; n = 60) or neoadjuvant endocrine therapy (NAE; n = 55) were selected. PIK3CA exon 9 and exon 20 mutations were screened by high resolution melting analysis and confirmed by Sanger sequence. PTEN expression was evaluated by immunohistochemistry. The relationships among PIK3CA mutations, PTEN expression, clinicopathological features, the pathological effect of neoadjuvant therapy, recurrence-free survival (RFS) and overall survival were analyzed | ||
| 520 | |a RESULTS: Among 115 patients, PIK3CA mutations and low PTEN expression before treatment were detected in 35 patients (30.4%) and in 28 patients (24.3%), respectively. In the NAC group, tumor with PIK3CA mutations showed significantly poorer response than tumor with PIK3CA wild-type (p = 0.03). On the other hand, in the NAE group, there was no significant difference in pathological therapeutic effect between tumor with PIK3CA mutations and tumor with PIK3CA wild-type (p = 0.54). In the NAC group, the log-rank test showed no difference in RFS between patients with PIK3CA mutations and PIK3CA wild-type (p = 0.43), but patients with low PTEN expression showed significantly worse RFS compared to patients with high PTEN expression (5 year RFS 0.64 vs. 0.87, p = 0.01). In the Cox proportional hazards model for RFS, PTEN expression, progesterone receptor, and pathological therapeutic effect were predictive factors for time to recurrence (All p < 0.05) | ||
| 520 | |a CONCLUSIONS: PIK3CA mutations are associated with resistance to NAC but do not affect the response to NAE. Low PTEN expression does not affect response to either NAC or NAE but correlates with shorter RFS in patients who received NAC. These biomarkers will be further evaluated for clinical use to treat postmenopausal luminal breast cancer patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Breast neoplasms | |
| 650 | 4 | |a Neoadjuvant therapy | |
| 650 | 4 | |a PTEN Phosphohydrolase | |
| 650 | 4 | |a Phosphatidylinositol 3-Kinases/genetics | |
| 650 | 4 | |a Prognosis | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a PTEN Phosphohydrolase |2 NLM | |
| 650 | 7 | |a EC 3.1.3.67 |2 NLM | |
| 650 | 7 | |a Class I Phosphatidylinositol 3-Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.1.137 |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a PTEN protein, human |2 NLM | |
| 650 | 7 | |a EC 3.1.3.67 |2 NLM | |
| 650 | 7 | |a PIK3CA protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.1.137 |2 NLM | |
| 700 | 1 | |a Nakamura, Rikiya |e verfasserin |4 aut | |
| 700 | 1 | |a Ishige, Takayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Sangai, Takafumi |e verfasserin |4 aut | |
| 700 | 1 | |a Sakakibara, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Fujimoto, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Ishigami, Emi |e verfasserin |4 aut | |
| 700 | 1 | |a Masuda, Takahito |e verfasserin |4 aut | |
| 700 | 1 | |a Nakagawa, Ayako |e verfasserin |4 aut | |
| 700 | 1 | |a Teranaka, Ryotaro |e verfasserin |4 aut | |
| 700 | 1 | |a Ota, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Itoga, Sakae |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Naohito |e verfasserin |4 aut | |
| 700 | 1 | |a Nagashima, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Otsuka, Masayuki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d 2001 |g 23(2023), 1 vom: 27. Apr., Seite 384 |w (DE-627)NLM111431948 |x 1471-2407 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:27 |g month:04 |g pages:384 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12885-023-10853-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 1 |b 27 |c 04 |h 384 | ||